NDAINJECTIONINJECTABLE
Approved
Sep 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ERYTHROCIN (erythromycin lactobionate) by Pfizer is clinical pharmacology erythromycin diffuses readily into most body fluids. Approved for penicillin-allergic patients, the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below, the severity of the infection requires immediate high serum levels of erythromycin. First approved in 1986.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ERYTHROCIN (erythromycin lactobionate) is an intravenous macrolide antibiotic that treats serious infections in penicillin-allergic patients by inhibiting bacterial protein synthesis via 50S ribosomal subunit binding. It is indicated for infections caused by susceptible gram-positive and gram-negative organisms including Staphylococcus aureus, Streptococcus species, Legionella pneumophila, and Mycoplasma pneumoniae when immediate high serum levels are required.
LOE Approaching
Product is approaching loss of exclusivity with high competitive pressure (30/100), indicating declining team investment and transition to generic support functions.
Mechanism of Action
CLINICAL PHARMACOLOGY Erythromycin diffuses readily into most body fluids. In the absence of meningeal inflammation, low concentrations are normally achieved in the spinal fluid but the passage of the drug across the blood-brain barrier increases in meningitis. Erythromycin crosses the placental…
Worked on ERYTHROCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.